Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06108063 · ClinicalTrials.gov registry record · Phase 1
Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan
A Phase 1 study of Knee Arthroplasty, Total, sponsored by Steadman Philippon Research Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT06108063 is a Phase 1 study of Knee Arthroplasty, Total that is actively recruiting participants, run by Steadman Philippon Research Institute. The registered enrollment target is 120 participants, below the 1,878-participant average among 3 other Knee Arthroplasty, Total trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06108063, a Phase 1 study of Knee Arthroplasty, Total, is actively recruiting participants, sponsored by Steadman Philippon Research Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the efficacy of Losartan use post-operatively for reducing or preventing the development of arthrofibrosis and the associated adverse impacts on clinical outcomes.
Conditions Studied
Interventions
- DRUG Losartan
- DRUG Placebo - Losartan
Study Locations (1)
Colorado
- The Steadman Clinic - Vail
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-03-06 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06108063
The ClinicalTrials.gov registry entry for NCT06108063 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,878-participant average among 3 other Knee Arthroplasty, Total trials with a reported enrollment target (94% lower). The listed sponsor is Steadman Philippon Research Institute, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Knee Arthroplasty, Total appearing as the primary indexed condition, and to 2 interventions - of which Losartan is the first listed.
NCT06108063 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT06108063 about?
NCT06108063 is a clinical study titled "Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan". The purpose of this study is to evaluate the efficacy of Losartan use post-operatively for reducing or preventing the development of arthrofibrosis and the associated adverse impacts on clinical outcomes.
What is the current status of trial NCT06108063?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2024-03-06. Estimated completion is 2027-06-30.
What conditions does trial NCT06108063 study?
This clinical trial studies the following conditions: Knee Arthroplasty, Total.
What interventions are being tested in trial NCT06108063?
The interventions under investigation include: Losartan (DRUG), Placebo - Losartan (DRUG).
Who is sponsoring clinical trial NCT06108063?
This trial is sponsored by Steadman Philippon Research Institute, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06108063 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Knee Arthroplasty, Total
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.